The study “Ambient AI Tool Adoption in US Hospitals and Associated Factors,” published in the January Health Information Technology issue of The American Journal of Managed Care® (AJMC®), detailed a study finding that 62.6% of hospitals running Epic have adopted ambient artificial intelligence (AI) scribe tools, with adoption skewing toward larger, nonprofit, higher-margin, and higher-workload hospitals, and notable geographic disparities favoring the South over the Midwest.
In its article, Becker's Hospital Review cited AJMC’s 62.6% adoption figure to establish just how quickly ambient AI scribes have spread through major health systems, using that rapid uptake as the premise for its broader argument that governance and transparency around these tools need to catch up before their use becomes mandatory.
In the interview “Oral vs Injectable GLP-1 Cost-Saving Strategies: Eric Levin,” published on AJMC, Eric Levin, CEO of Scripta, explained that although oral glucagon-like peptide-1s (GLP-1s) should theoretically cost less to manufacture than injectables, insurance reimbursement rates for the 2 formulations are currently comparable. He advised patients to check coverage, look into manufacturer assistance programs, and consider cash-pay options like GoodRx.
HR Executive cited AJMC’s interview to note that despite lower self-pay list prices for oral GLP-1s, reimbursement parity with injectables means employers shouldn’t assume oral formulations are automatically the cheaper path. That supports the interview’s broader argument that pharmacy benefit choices now carry stop-loss implications employers can’t ignore.
